Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma

References

• ZuccaERoggeroEPinottiGPatterns of survival in mantle cell lymphomaAnn Oncol1995632572627612491
   PubMed Web of Science ®Google Scholar
• RomagueraJEFayadLRodriguezMAHigh rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJ Clin Oncol200523287013702316145068
   PubMed Web of Science ®Google Scholar
• LenzGDreylingMHosterEImmunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)J Clin Oncol20052391984199215668467
   PubMed Web of Science ®Google Scholar
• ForstpointnerRDreylingMReppRThe addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2004104103064307115284112
   PubMed Web of Science ®Google Scholar
• WangMOkiYProBPhase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphomaJ Clin Oncol200927315213521819770379
   PubMed Web of Science ®Google Scholar
• O’ConnorOAMoskowitzCPortlockCPatients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trialBr J Haematol20091451343919220284
   PubMed Web of Science ®Google Scholar
• HabermannTMLossosISJusticeGLenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphomaBr J Haematol2009145334434919245430
   PubMed Web of Science ®Google Scholar
• GeislerCMantle cell lymphoma: are current therapies changing the course of disease?Curr Oncol Rep200911537137719679012
   PubMed Web of Science ®Google Scholar
• SehgalSNBakerHVézinaCRapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterizationJ Antibiot (Tokyo)197528107277321102509
   PubMed Web of Science ®Google Scholar
• DrakosERassidakisGZMedeirosLJMammalian target of rapamycin (mTOR) pathway signalling in lymphomasExpert Rev Mol Med200810e418241520
   PubMedGoogle Scholar
• GaumannASchlittHJGeisslerEKImmunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycinTranspl Int200821320721718069922
   PubMed Web of Science ®Google Scholar
• BjornstiMAHoughtonPJThe TOR pathway: a target for cancer therapyNat Rev Cancer20044533534815122205
   PubMed Web of Science ®Google Scholar
• GibbonsJJAbrahamRTYuKMammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growthSemin Oncol200936Suppl 3S3S1719963098
   PubMedGoogle Scholar
• CafferkeyRMcLaughlinMMYoungPRJohnsonRKLiviGPYeast TOR (DRR) proteins: amino-acid sequence alignment and identification of structural motifsGene199414111331368163165
   PubMed Web of Science ®Google Scholar
• HayNSonenbergNUpstream and downstream of mTORGenes Dev200418161926194515314020
   PubMed Web of Science ®Google Scholar
• JozwiakJJozwiakSGrzelaTLazarczykMPositive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathwayNeuromolecular Med20057428729616391386
   PubMed Web of Science ®Google Scholar
• PotterCJPedrazaLGXuTAkt regulates growth by directly phosphorylating Tsc2Nat Cell Biol20024965866512172554
   PubMed Web of Science ®Google Scholar
• WullschlegerSLoewithRHallMNTOR signaling in growth and metabolismCell2006124347148416469695
   PubMed Web of Science ®Google Scholar
• VignotSFaivreSAguirreDRaymondEmTOR-targeted therapy of cancer with rapamycin derivativesAnn Oncol200516452553715728109
   PubMed Web of Science ®Google Scholar
• WullschlegerSLoewithROppligerWHallMNMolecular organization of target of rapamycin complex 2J Biol Chem200528035306973070416002396
   PubMed Web of Science ®Google Scholar
• JulienLACarriereAMoreauJRouxPPmTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signalingMol Cell Biol201030490892119995915
   PubMed Web of Science ®Google Scholar
• GingrasACGygiSPRaughtBRegulation of 4E-BP1 phosphorylation: a novel two-step mechanismGenes Dev199913111422143710364159
   PubMed Web of Science ®Google Scholar
• MirshahiPToprakSKFaussatAMMalignant hematopoietic cells induce an increased expression of VEGFR-1 and VEGFR-3 on bone marrow endothelial cells via AKT and mTOR signalling pathwaysBiochem Biophys Res Commun200634931003101016959214
   PubMed Web of Science ®Google Scholar
• BaldoPCeccoSGiacominELazzariniRRosBMarastoniSmTOR pathway and mTOR inhibitors as agents for cancer therapyCurr Cancer Drug Targets20088864766519075588
   PubMed Web of Science ®Google Scholar
• BrownVISeifAEReidGSTeacheyDTGruppSANovel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative diseaseImmunol Res2008421–38410518716718
   PubMed Web of Science ®Google Scholar
• AvellinoRRomanoSParasoleRRapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cellsBlood200510641400140615878982
   PubMed Web of Science ®Google Scholar
• CrazzolaraRCisterneAThienMPotentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemiaBlood2009113143297330619196656
   PubMed Web of Science ®Google Scholar
• GuLGaoJLiQRapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosisLeukemia200822112091209618685609
   PubMed Web of Science ®Google Scholar
• KharasMGDeaneJAWongSPhosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cellsBlood2004103114268427514976048
   PubMed Web of Science ®Google Scholar
• XuQSimpsonSESciallaTJBaggACarrollMSurvival of acute myeloid leukemia cells requires PI3 kinase activationBlood2003102397298012702506
   PubMed Web of Science ®Google Scholar
• FolloMYMongiorgiSBosiCThe Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferationCancer Res20076794287429417483341
   PubMed Web of Science ®Google Scholar
• HoangBBenavidesAShiYFrostPLichtensteinAEffect of autophagy on multiple myeloma cell viabilityMol Cancer Ther2009871974198419509276
   PubMed Web of Science ®Google Scholar
• FrostPShiYHoangBLichtensteinAAKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cellsOncogene200726162255226217016437
   PubMed Web of Science ®Google Scholar
• FaragSSZhangSJansakBSPhase II trial of temsirolimus in patients with relapsed or refractory multiple myelomaLeuk Res200933111475148019261329
   PubMed Web of Science ®Google Scholar
• DuttonAReynoldsGMDawsonCWYoungLSMurrayPGConstitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving Akt kinase and mTORJ Pathol2005205449850615714459
   PubMed Web of Science ®Google Scholar
• GuptaMAnsellSMNovakAJKumarSKaufmannSHWitzigTEInhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2Blood2009114142926293519641186
   PubMed Web of Science ®Google Scholar
• PopIVPopLMGhetieMAVitettaESTargeting mammalian target of rapamycin to both downregulate and disable the P-glycoprotein pump in multidrug-resistant B-cell lymphoma cell linesLeuk Lymphoma20095071155116219557637
   PubMed Web of Science ®Google Scholar
• GasperiniPTosatoGTargeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphomaLeukemia200923101867187419554030
   PubMed Web of Science ®Google Scholar
• NepomucenoRRBalatoniCENatkunamYSnowALKramsSMMartinezOMRapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomasCancer Res200363154472448012907620
   PubMed Web of Science ®Google Scholar
• LeseuxLHamdiSMAl SaatiTSyk-dependent mTOR activation in follicular lymphoma cellsBlood2006108134156416216912221
   PubMed Web of Science ®Google Scholar
• GuptaMDillonSRZiesmerSCA proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activationBlood2009113215206521619321861
   PubMed Web of Science ®Google Scholar
• RingshausenIPeschelCDeckerTMammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic optionLeuk Lymphoma2005461111915621776
   PubMed Web of Science ®Google Scholar
• DeckerTHippSRingshausenIRapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivinBlood2003101127828512393642
   PubMed Web of Science ®Google Scholar
• DeckerTSandherrMGoetzeKOelsnerMRingshausenIPeschelCA pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLLAnn Hematol200988322122718704419
   PubMed Web of Science ®Google Scholar
• JaresPColomerDCampoEGenetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeuticsNat Rev Cancer200771075076217891190
   PubMed Web of Science ®Google Scholar
• DecaudinDMantle cell lymphoma: a biological and therapeutic paradigmLeuk Lymphoma200243477378112153164
   PubMed Web of Science ®Google Scholar
• SherrCJD-type cyclinsTrends Biochem Sci19952051871907610482
   PubMed Web of Science ®Google Scholar
• Dal ColJZancaiPTerrinLDistinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphomaBlood2008111105142515118339899
   PubMed Web of Science ®Google Scholar
• RudeliusMPittalugaSNishizukaSConstitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphomaBlood200610851668167616645163
   PubMed Web of Science ®Google Scholar
• HarituniansTMoriAO’KellyJLuongQTGilesFJKoefflerHPAntiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphomaLeukemia200721233333917136116
   PubMed Web of Science ®Google Scholar
• LeseuxLLaurentGLaurentCPKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphomaBlood2008111128529117855629
   PubMed Web of Science ®Google Scholar
• YounesATherapeutic activity of mTOR inhibitors in mantle cell lymphomaAutophagy20084570770918469512
   PubMed Web of Science ®Google Scholar
• PeponiEActivation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphomaAm J Pathol200616962171218017148679
   PubMed Web of Science ®Google Scholar
• HippSRingshausenIOelsnerMBognerCPeschelCDeckerTInhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cellsHaematologica200590101433143416219581
   PubMed Web of Science ®Google Scholar
• WolowiecDBergerFFfrenchPBryonPAFfrenchMCDK1 and cyclin A expression is linked to cell proliferation and associated with prognosis in non-Hodgkin’s lymphomasLeuk Lymphoma1999351–214715710512172
   PubMed Web of Science ®Google Scholar
• GelebartPAnandMArmaniousHConstitutive activation of the Wnt canonical pathway in mantle cell lymphomaBlood2008112135171517918787224
   PubMed Web of Science ®Google Scholar
• YazbeckVYBuglioDGeorgakisGVTemsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphomaExp Hematol200836444345018343280
   PubMed Web of Science ®Google Scholar
• GiatromanolakiAKoukourakisMIPezzellaFPhosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin’s lymphomas and correlate with hypoxia inducible factor activationHematol Oncol200826421922418461646
   PubMed Web of Science ®Google Scholar
• KoomagiRZintlFSauerbreyAVolmMVascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reactionClin Cancer Res20017113381338411705851
   PubMed Web of Science ®Google Scholar
• HazarBPaydasSZorludemirSSahinBTuncerIPrognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin’s lymphomaLeuk Lymphoma200344122089209314959852
   PubMed Web of Science ®Google Scholar
• KuramotoKSakaiAShigemasaKHigh expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin’s lymphomaBr J Haematol2002116115816111841410
   PubMed Web of Science ®Google Scholar
• PottiAGantiAKKargasSKochMImmunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphomaAnticancer Res20022252899290112530014
   PubMed Web of Science ®Google Scholar
• GalimbertiSNagyBPalumboGAVascular endothelial growth factor polymorphisms in mantle cell lymphomaActa Haematol20101232919520029173
   PubMed Web of Science ®Google Scholar
• RouxPPShahbazianDVuHRAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translationJ Biol Chem200728219140561406417360704
   PubMed Web of Science ®Google Scholar
• KurieJMMorseHCIIIPrincipatoMAv-myc and v-raf act synergistically to induce B-cell tumors in pristane-primed adult BALBC miceOncogene1990545775822183159
   PubMed Web of Science ®Google Scholar
• NagyBGalimbertiSBenedettiERAF-1 over-expression does condition survival of patients affected by aggressive mantle cell lymphomaLeuk Res200731111595159717572489
   PubMed Web of Science ®Google Scholar
• NagyBLundánTLarramendyMLAbnormal expression of apoptosis-related genes in hematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphomaBr J Haematol2003120344344441
   Web of Science ®Google Scholar
• MillsJRHippoYRobertFmTORC1 promotes survival through translational control of Mcl-1Proc Natl Acad Sci U S A200810531108531085818664580
   PubMed Web of Science ®Google Scholar
• RinaldiAKweeITaborelliMGenomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphomaBr J Haematol2006132330331616409295
   PubMed Web of Science ®Google Scholar
• HudesGRBerkenblitAFeingoldJAtkinsMBRiniBIDutcherJClinical trial experience with temsirolimus in patients with advanced renal cell carcinomaSemin Oncol200936Suppl 3S26S3619963097
   PubMedGoogle Scholar
• MitaMMMitaARowinskyEKMammalian target of rapamycin: a new molecular target for breast cancerClin Breast Cancer20034212613712864941
   PubMedGoogle Scholar
• MitaMMTolcherAWThe role of mTOR inhibitors for treatment of sarcomasCurr Oncol Rep20079431632217588357
   PubMedGoogle Scholar
• TolcherAWNovel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptorJ Urol2004171S4143 discussion S44.14713752
   PubMedGoogle Scholar
• CoiffierBRibragVExploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignanciesLeuk Lymphoma200950121916193019757306
   PubMed Web of Science ®Google Scholar
• BoniJPHugBLeisterCSonnichsenDIntravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerationsSemin Oncol200936Suppl 3S18S2519963096
   PubMedGoogle Scholar
• WitzigTEGeyerSMGhobrialIPhase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphomaJ Clin Oncol200523235347535615983389
   PubMed Web of Science ®Google Scholar
• SankhalaKMitaAKellyKMahalingamDGilesFMitaMThe emerging safety profile of mTOR inhibitors, a novel class of anticancer agentsTarget Oncol20094213514219381454
   PubMed Web of Science ®Google Scholar
• AnsellSMInwardsDJRowlandKMJrLow-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupCancer2008113350851418543327
   PubMed Web of Science ®Google Scholar
• HessGHerbrechtRRomagueraJPhase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphomaJ Clin Oncol200927233822382919581539
   PubMed Web of Science ®Google Scholar
• HessGRomagueraJHerbrechtRTemsirolimus for the treatment of patients with relapsed or refractory mantle cell lymphoma. Supportive efficacy analyses from the phase 3 studyHaematologica200994Suppl 2S391 Abstract 0973.
   Google Scholar
• AnsellSMTangHKurtinPA phase II study of temsirolimus (CCI-779) in combination with rituximab in patients with relapsed or refractory mantle cell lymphoma [ASH Annual Meeting Abstracts]Blood20091141665
   Web of Science ®Google Scholar
• ReederCBGornetMKHabermannTMA phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL) [ASH Annual Meeting Abstracts]Blood2007110121
   Web of Science ®Google Scholar